Arrivent Biopharma received FDA IND clearance for ARR-002 (AV-P138-ADC), an antibody-drug conjugate aimed initially at ovarian and endometrial cancers, with broader potential across solid tumors. The company said a Phase I trial is expected to open in the second half of the year. ARR-002 represents Arrivent’s ADC development step forward within its pipeline as it moves into first-in-human testing. The clearance follows the FDA’s review of the compound’s preclinical package and enables initiation of clinical evaluation. For investors tracking next-wave ADCs, the clearance signals continued expansion of early-stage solid tumor programs as companies seek differentiated targets and payload combinations in the clinic.